Sanofi’s American depositary shares are falling sharply in the latest session, with price action consistent with an ex-dividend reset combined with incremental selling after a major broker downgrade. Sanofi’s investor materials show an early-May 2026 ex-dividend schedule tied to the annual dividend, which typically causes the stock price to open lower by approximately the value of the dividend as new buyers no longer receive the upcoming payment. (sanofi.com)

Adding to the ex-dividend pressure, Morgan Stanley moved its rating on Sanofi from Overweight to Equal Weight in a note published late last week. The downgrade hit sentiment following Sanofi’s recent results update, where the company reiterated its 2026 framework, leaving the stock more exposed to external re-rating calls rather than a new company-specific catalyst. (marketbeat.com)

Investors will likely focus on whether additional brokers follow with downgrades and whether the stock stabilizes once the dividend-related adjustment passes. Near-term price action may remain sensitive to pipeline and longer-term growth debates that have been surfacing in recent analyst commentary around the company’s reliance on key franchises. (investing.com)